Table 4.
Multivariate Cox regression analyses for DFS and OS of GC patients
| Variables | Disease-free survival | Overall survival | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Age (years) | ||||||
| < 58 | Ref. | Ref. | ||||
| ≥ 58 | 1.12 | 0.94–1.33 | 0.225 | 1.34 | 1.12–1.61 | 0.002 |
| Tumor location | ||||||
| GEJ + Upper 1/3 | Ref. | Ref. | ||||
| Middle 1/3 | 1.02 | 0.82–1.27 | 0.845 | 1.05 | 0.84–1.31 | 0.691 |
| Lower 1/3 | 0.86 | 0.70–1.05 | 0.139 | 0.88 | 0.72–1.08 | 0.230 |
| Tumor size | ||||||
| < 3.2 cm | Ref. | Ref. | ||||
| ≥ 3.2 cm | 1.17 | 0.96–1.42 | 0.122 | 1.17 | 0.95–1.43 | 0.133 |
| Histologic grade | ||||||
| Well-moderately | Ref. | Ref. | ||||
| Poorly | 1.12 | 0.87–1.44 | 0.382 | 1.07 | 0.83–1.38 | 0.606 |
| T category | ||||||
| T1 | Ref. | Ref. | ||||
| T2 | 1.79 | 1.07–3.00 | 0.026 | 1.94 | 1.13–3.35 | 0.017 |
| T3 | 2.93 | 1.75–4.92 | < 0.001 | 3.31 | 1.92–5.71 | < 0.001 |
| T4a | 4.68 | 2.92–7.50 | < 0.001 | 5.54 | 3.36–9.13 | < 0.001 |
| T4b | 6.68 | 3.54–12.60 | < 0.001 | 8.99 | 4.63–17.44 | < 0.001 |
| N category | ||||||
| N0 | Ref. | Ref. | ||||
| N1 | 1.61 | 1.15–2.26 | 0.006 | 1.69 | 1.20–2.39 | 0.003 |
| N2 | 2.58 | 1.88–3.52 | < 0.001 | 2.46 | 1.78–3.40 | <0.001 |
| N3a | 4.70 | 3.46–6.38 | < 0.001 | 4.78 | 3.49–6.55 | < 0.001 |
| N3b | 7.18 | 4.99–10.33 | < 0.001 | 7.97 | 5.48–11.60 | < 0.001 |
| VELIPI | ||||||
| Negative | Ref. | Ref. | ||||
| Positive | 1.27 | 1.03–1.57 | 0.027 | 1.11 | 0.89–1.37 | 0.357 |
| Adjuvant treatment | ||||||
| No | Ref. | Ref. | ||||
| Single drugs | 0.62 | 0.45–0.84 | 0.002 | 0.57 | 0.41–0.79 | 0.001 |
| Double drugs | 0.55 | 0.41–0.72 | < 0.001 | 0.56 | 0.42–0.75 | < 0.001 |
| Triple drugs | 0.64 | 0.47–0.88 | 0.005 | 0.58 | 0.42–0.81 | 0.001 |
| CRT | 0.66 | 0.47–0.94 | 0.021 | 0.60 | 0.42–0.86 | 0.005 |
| TD | ||||||
| Absent | Ref. | Ref. | ||||
| Present | 1.75 | 1.42–2.14 | < 0.001 | 1.93 | 1.57–2.38 | < 0.001 |
Abbreviations: CI confidence interval, DFS disease-free survival, GC gastric cancer, GEJ gastroesophageal junction, HR hazard ratio, LNs lymph nodes, OS overall survival, PSM propensity score matching, Ref. reference, TD tumor deposit, VELIPI vascular emboli, lymphatic, and perineural invasion